stockrow
Saturday 7 November 2026
Export SLDB’s income statement to Excel — free account
Solid Biosciences Inc.
SLDB Healthcare Biotechnology
Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million.
- EPS
- +25.6%
- Free cash flow
- −39.6%
Quarter to September 2026, against a year earlier
6.57
0.39
+6.31%
Follow SLDB
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
11.48 | 13.24 | 12.59 | 5.65 | |
Current Ratio |
11.99 | 13.82 | 13.10 | 6.14 | |
Net Debt/EBITDA |
5.96 | 6.48 | 6.63 | 3.81 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 0.96 | 0.83 | 1.08 | |
Capex/Depreciation |
0.48 | 0.15 | 0.74 | 1.71 | |
Interest Coverage |
— | — | — | (9,880.60) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.30) | (0.37) | (0.43) | (0.61) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.30) | (0.37) | (0.43) | (0.62) | |
Cash per Share |
2.31 | 2.63 | 3.47 | 2.16 | |
Shareholders Equity per Share |
2.27 | 2.60 | 3.41 | 2.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.27 | 2.60 | 3.41 | 2.06 | |
Free Cash Flow |
(46.04) | (52.74) | (47.39) | (54.03) | |
Working Capital |
334.74 | 366.52 | 366.51 | 171.98 | |
Capital Expenditures |
(0.50) | (0.15) | (0.16) | (0.48) | |
Net Current Asset Value |
317.40 | 348.60 | 348.03 | 152.93 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
5.83 | 4.53 | 6.00 | 3.73 | |
Average Assets |
331.91 | 364.44 | 383.40 | 210.60 | |
Average Common Equity |
280.03 | 316.18 | 334.30 | 158.63 |
Columns are period end dates · fundamentals updated 6 Nov 2026